文献速递泌尿男性生殖肿瘤

剂量密集型甲氨蝶呤、长春碱、多柔比星与顺铂或吉西他滨与顺铂作为非转移性肌层浸润性膀胱癌患者围手术期化疗:GETUG-AFU V05 VESPER 试验结果

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
PubMed 文献 · J Clin Oncol · 2022-03-07

VESPER 试验在 28 个法国中心随机分配 500 例非转移性肌层浸润性膀胱癌患者,比较 dd-MVAC 与 GC 围手术期化疗。全组 3 年 PFS 未达主要终点(64% v 56%,HR=0.77,P=.066),但 dd-MVAC 组至进展时间显著延长(69% v 58%,HR=0.68,P=.014)。新辅助亚组 3 年 PFS 显著提高(66% v 56%,HR=0.70,P=.025)。

要点

  • 全组 3 年 PFS 未达主要终点:dd-MVAC 64% v GC 56%,HR=0.77(95%CI 0.57–1.02),P=.066。
  • 全组至进展时间 dd-MVAC 组显著延长:3 年 69% v 58%,HR=0.68(95%CI 0.50–0.93),P=.014。
  • 新辅助亚组 3 年 PFS dd-MVAC 显著高于 GC:66% v 56%,HR=0.70(95%CI 0.51–0.96),P=.025。

核心结论

  • VESPER 试验中 dd-MVAC 较 GC 改善 3 年 PFS;新辅助组 dd-MVAC 组膀胱肿瘤局部控制更好且 3 年 PFS 显著改善。

研究设计与样本

  • 2013 年 2 月至 2018 年 3 月,28 个法国中心随机分配 500 例非转移性肌层浸润性膀胱癌患者。
  • 患者接受 dd-MVAC 每 2 周一次共 6 周期或 GC 每 3 周一次共 4 周期,术前(新辅助组)或术后(辅助组)给药。
  • 主要终点为 3 年无进展生存(PFS),次要终点为至进展时间和总生存。

主要发现

  • 437 例(88%)接受新辅助化疗;dd-MVAC 组 60% 完成计划 6 周期,GC 组 84% 完成 4 周期,随后分别 91% 和 90% 接受手术。
  • 器官局限缓解(<ypT3N0)dd-MVAC 组更常见:77% v 63%,P=.001。
  • 辅助组中 dd-MVAC 组 40% 完成 6 周期,GC 组 81% 完成 4 周期。
  • 全组 3 年 PFS dd-MVAC 组 64% v GC 组 56%,HR=0.77(95%CI 0.57–1.02),P=.066,未达主要终点。
  • 全组至进展时间 dd-MVAC 组显著更长:3 年 69% v 58%,HR=0.68(95%CI 0.50–0.93),P=.014;新辅助组 3 年 PFS dd-MVAC 组 66% v 56%,HR=0.70(95%CI 0.51–0.96),P=.025。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal perioperative chemotherapy regimen for patients with nonmetastatic muscle-invasive bladder cancer is not defined. PATIENTS AND METHODS: Between February 2013 and March 2018, 500 patients were randomly assigned in 28 French centers and received either six cycles of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) once every 2 weeks or four cycles of gemcitabine and cisplatin (GC) once every 3 weeks before surgery (neoadjuvant group) or after surgery (adjuvant group). We report the primary end point of the GETUG-AFU V05 VESPER trial (ClinicalTrials.gov identifier: NCT01812369): progression-free survival (PFS) at 3 years. Secondary end points were time to progression and overall survival. RESULTS: Four hundred thirty-seven patients (88%) received neoadjuvant chemotherapy; 60% of patients received the planned six cycles in the dd-MVAC arm, 84% received four cycles in the GC arm, and thereafter, 91% and 90% of patients underwent surgery, respectively. Organ-confined response (< ypT3N0) was observed more frequently in the dd-MVAC arm (77% v 63%, P = .001). In the adjuvant group, 40% of patients received six cycles in the dd-MVAC arm, and 81% of patients received four cycles in the GC arm. For all patients in the clinical trial, 3-year PFS was improved in the dd-MVAC arm, but the study did not meet its primary end point (3-year rate: 64% v 56%, hazard ratio [HR] = 0.77 [95% CI, 0.57 to 1.02], P = .066); nevertheless, the dd-MVAC arm was associated with a significantly longer time to progression (3-year rate: 69% v 58%, HR = 0.68 [95% CI, 0.50 to 0.93], P = .014). In the neoadjuvant group, PFS at 3 years was significantly higher in the dd-MVAC arm (66% v 56%, HR = 0.70 [95% CI, 0.51 to 0.96], P = .025). CONCLUSION: In the VESPER trial, dd-MVAC improved 3-years PFS over GC. In the neoadjuvant group, a better bladder tumor local control and a significant improvement in 3-year PFS were observed in the dd-MVAC arm.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pfister C, Gravis G, Fléchon A, et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022. PMID: 35254888. doi:10.1200/JCO.21.02051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。